Exscientia Investor Presentation Deck
March 2024, 93 slides
  1. Exscientia
  2. Related Decks
  3. Investor Presentation Decks
precision designed medicine march | Exscientia
forward looking statements | Exscientia
patient first integrated technologies to discover design and develop precision medicines | Exscientia
delivering better pipeline candidates faster | Exscientia
ways we can improve probability of success | Exscientia
positioned us well for long term growth | Exscientia
advancing multiple programmes in | Exscientia
solution integrating knowledge of the patient and drug precision medicine | Exscientia
why are our clinical candidates different | Exscientia
pursuing high quality differentiated medicines | Exscientia
partnership highlights | Exscientia
our strategy maintains balance sheet strength | Exscientia
supporting slides | Exscientia
operating at the interface of human ingenuity and technology | Exscientia
expanding technologies enhance value creation | Exscientia
expanded technologies have translated to partnerships | Exscientia
target selection | Exscientia
target generation engine | Exscientia
custom trained to refine biological relevance of targets | Exscientia
enhanced research | Exscientia
precision design | Exscientia
why learning beats screening | Exscientia
drug discovery is a learning problem two critical questions | Exscientia
active learning leads to creative breakthroughs | Exscientia
extensive proprietary data generation capabilities | Exscientia
precision objectives for precision design | Exscientia
data and model agnostic | Exscientia
| Exscientia
and scalable toolbox | Exscientia
design of kinase inhibitors | Exscientia
| Exscientia
integrating learning into the loop | Exscientia
our new facility | Exscientia
closing the loop | Exscientia
our studio | Exscientia
synthesis with driven design in mind driven | Exscientia
connectivity | Exscientia
precision medicine a he | Exscientia
our differentiated process | Exscientia
exalt study first driven functional precision medicine platform to directly improve cancer treatment patient outcomes | Exscientia
exalt study results | Exscientia
trials expansion of precision medicine platform a i | Exscientia
cancer is a heterogenous disease | Exscientia
defining patient selection during drug design | Exscientia
advancing to the clinic | Exscientia
design patient centric drugs with an improved probability of success | Exscientia
inhibitor elucidate phase ongoing beak at | Exscientia
elucidate phase ongoing in advanced solid | Exscientia
elucidate phase ongoing in advanced solid | Exscientia
inhibition provides broad oncology opportunity | Exscientia
precision design to effectiveness | Exscientia
our candidate resolves critical design issues | Exscientia
is highly effective in classical models | Exscientia
half life benefit risk | Exscientia
evaluating the potential of in primary tissue | Exscientia
expanding potential efficacy with rational combinations | Exscientia
proposed of exposure | Exscientia
theta in licensed by phase study ongoing a | Exscientia
theta in licensed by in august | Exscientia
large failures on an attractive target nome a octets | Exscientia
our approach | Exscientia
phase to start in | Exscientia
inhibitor moving into patient trials a | Exscientia
inhibition leads to differentiation of cells | Exscientia
inhibition promotes cell differentiation in | Exscientia
inhibition drives to quiescence oes | Exscientia
highly differentiated inhibitor | Exscientia
precision design to therapeutic window | Exscientia
delivering quality candidate against a novel | Exscientia
technology in action precision design of | Exscientia
active learning enabled breakthrough for | Exscientia
benefit of reversible target engagement on platelets | Exscientia
induces myeloid differentiation | Exscientia
with first line soc and targeted therapies | Exscientia
inhibits growth in | Exscientia
with approved soc and targeted therapies | Exscientia
variability observed in induced cell differentiation a | Exscientia
| Exscientia
summary | Exscientia
malt enabling studies ongoing | Exscientia
potential to avoid key class wide safety concern | Exscientia
malt inhibiting malignant cell signaling in cell lymphomas | Exscientia
precision designed to therapeutic index | Exscientia
avoiding a | Exscientia
malt competitor profiles | Exscientia
technology in action precision design of he | Exscientia
leveraged physics based predictive modelling | Exscientia
inhibits model growth in | Exscientia
inhibits primary human cell proliferation | Exscientia
has a low predicted risk of | Exscientia
malt | Exscientia
summary | Exscientia
| Exscientia
See More
Exscientia
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Cancer
Inhibitor
Medicine
Drug discovery
Ovarian cancer
Drug candidate
Recent decks by Exscientia
Results
March 2024
Investor Day
January 2024
Investor Presentation
November 2023
Results
November 2023
See all presentations by Exscientia (14 decks)
Related decks
Nuvectis Pharma
Investor Presentation
January 2024
AstraZeneca
Results
July 2021
Alkermes
Investor Day
March 2021
BenevolentAI
Investor Presentation
October 2022
Allarity Therapeutics
Investor Conference
September 2022
Nuvectis Pharma
Investor Presentation
July 2023
AstraZeneca
Investor Day
June 2021
Nuvectis Pharma
Investor Presentation
August 2023
Recent decks by Exscientia
See all presentations (14 decks)
Results
March 2024
Investor Day
January 2024
Investor Presentation
November 2023
Results
November 2023
Nuvectis Pharma
Investor Presentation
January 2024
AstraZeneca
Results
July 2021
Alkermes
Investor Day
March 2021
BenevolentAI
Investor Presentation
October 2022
Allarity Therapeutics
Investor Conference
September 2022
Nuvectis Pharma
Investor Presentation
July 2023
AstraZeneca
Investor Day
June 2021
Nuvectis Pharma
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io